-

Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001) announced today the acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research annual meeting. The study titled “Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV”, was accepted for the e poster session during the meeting. The details of the abstract viewing are below:

Abstract Control Number: 5232
Title: Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV
Session Type: E-Poster Session

Session Category: Clinical Research (Excluding Trials)
Session Title: Combination Immunotherapies

About Seneca Therapeutics

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products. Seneca Therapeutics is also developing armed versions of SVV-001 to selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

Contacts

Paul Hallenbeck
phallenbeck@senecatherapeutics.com

James Hussey
jhussey@senecatherapeutics.com

www.senecatherapeutics.com

Industry:

Seneca Therapeutics, Inc.

Release Summary
Seneca Therapeutics announces acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research Meeting April 10-15, 2021
Release Versions
English

Contacts

Paul Hallenbeck
phallenbeck@senecatherapeutics.com

James Hussey
jhussey@senecatherapeutics.com

www.senecatherapeutics.com

More News From Seneca Therapeutics, Inc.

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at Oncolytic Virotherapy Summit 2023 on December 13

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (STI), announced today that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses”. In his talk, Dr. Hallenbeck will discuss the challenges inherent in doing multiple (IV) intravenous administrations of oncolytic viruses, where the field is meeting these challenges, and present data on the development of multiple IV...

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at World Vaccine Congress November 28, 2023

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., announced today Dr. Paul Hallenbeck will present a talk titled “Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity”, during the World Vaccine Congress in Santa Clara, CA on November 28, 2023. In his talk, Dr. Hallenbeck will present data on the development of multiple IV technology for SVV-001, a clinical stage oncology product. “Seneca believes that having both multiple...

Seneca Therapeutics Announces Publication of TEM8 Review Article “TEM8 in Oncogenesis” in Cells Journal

PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells. The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett from Mt. Sinai Tisch Cancer Center and Dr. Paul Hallenbeck from Seneca Therapeutics. “In the article, we underline TEM8’s prognostic and predictive abilities in various solid tumors by (1) highlighting its association with more aggressive disease biolo...
Back to Newsroom